Curevac N.V. (CVAC) has released an update.
CureVac N.V., a leading mRNA biopharmaceutical company, has appointed Thaminda Ramanayake as its new Chief Business Officer, effective June 1, 2024. Ramanayake, with over 15 years of experience in biopharma development and deal-making, is expected to enhance CureVac’s strategic partnerships and advance its mRNA vaccine and therapeutic programs. His previous roles include key positions at Affini-T Therapeutics, Sanofi, BioMarin Pharmaceuticals, and Amgen, bringing a wealth of expertise in clinical collaborations, mergers and acquisitions, and strategic financing.
For further insights into CVAC stock, check out TipRanks’ Stock Analysis page.
